Celyad

Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer as FDA lifts hold
Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer as FDA lifts hold
Endpoints
Celyad
CAR-T
colorectal cancer
FDA
clinical trials
Flag link:
FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold to investigate 2 patient deaths
FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold to investigate 2 patient deaths
Endpoints
Celyad
FDA
patient deaths
CAR-T
clinical holds
Flag link:
Corporate and regulatory developments over the Christmas period
Corporate and regulatory developments over the Christmas period
EP Vantage
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Flag link:
SITC – the morning after the night before
SITC – the morning after the night before
EP Vantage
SITC
NextCure
Pieris
Celyad
Nektar
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
Novartis takes the long view on CAR-T, grabbing licenses on new tech for next-gen therapies
Novartis takes the long view on CAR-T, grabbing licenses on new tech for next-gen therapies
Endpoints
Novartis
CAR-T
cell therapy
Celyad
Flag link: